• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Amicus Therapeutics Inc.

    11/14/24 9:00:58 PM ET
    $FOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FOLD alert in real time by email
    SC 13G/A 1 tm2427858d3_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 

    (Amendment No. 12)

     

    Amicus Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock Par Value $0.01
    (Title of Class of Securities)

     

    03152W109
    (CUSIP Number)

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)

     

      ¨ Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 03152W109

     

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with
    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    15,376,197 (1) 

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    15,376,197 (1) 

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    15,376,197 (1) 

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    5.1% (2) 

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

           

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of (a) 8,246,592 shares of Common Stock and (b) 7,129,605 shares of Common Stock issuable upon exercise of certain warrants (the “Warrants”), which, in each case, are owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. 

    (2) Percentage based on (i) 296,590,931 shares of Common Stock outstanding as of July 26, 2024, as reported by the Issuer in its Form 10-Q for the quarterly period ended June 30, 2024 filed with the Securities and Exchange Commission on August 8, 2024 (the “Form 10-Q”), plus (ii) 7,129,605 shares of Common Stock issuable upon exercise of certain of the Warrants.

     

     

     

     

    CUSIP No. 03152W109

     

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

    number of
    shares
    beneficially
    owned by
    each
    reporting
    person with
    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    15,376,197 (3) 

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    15,376,197 (3) 

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    15,376,197 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    5.1% (4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

           

     

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of (a) 8,246,592 shares of Common Stock and (b) 7,129,605 shares of Common Stock issuable upon exercise of the Warrants, which, in each case, are owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. 

    (4) Percentage based on (i) 296,590,931 shares of Common Stock outstanding as of July 26, 2024, as reported by the Issuer in the Form 10-Q, plus (ii) 7,129,605 shares of Common Stock issuable upon exercise of certain of the Warrants.

     

     

     

     

    Item 1.

     

      (a) Name of Issuer

     

    Amicus Therapeutics, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    47 Hulfish Street, 

    Princeton, NJ 08542

     

    Item 2.

     

      (a) Names of Persons Filing

     

    Redmile Group, LLC
    Jeremy C. Green

     

      (b) Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    Jeremy C. Green
    c/o Redmile Group, LLC (NY Office)
    45 W. 27th Street, Floor 11
    New York, NY 10001

     

      (c) Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

     

      (d) Title of Class of Securities

     

    Common Stock Par Value $0.01

     

      (e) CUSIP Number

     

    03152W109

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

      (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

     

     

     

      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4. Ownership.

     

      (a) Amount beneficially owned:

     

    Redmile Group, LLC – 15,376,197 (1)
    Jeremy C. Green – 15,376,197 (1)

     

      (b) Percent of class:

     

    Redmile Group, LLC – 5.1% (2)
    Jeremy C. Green – 5.1% (2)

     

      (c) Number of shares as to which Redmile Group, LLC has:

     

      (i) Sole power to vote or to direct the vote:

     

    0

     

      (ii) Shared power to vote or to direct the vote:

     

    15,376,197 (1)

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    15,376,197 (1)

     

    Number of shares as to which Jeremy C. Green has:

     

      (i) Sole power to vote or to direct the vote:

     

    0

     

      (ii) Shared power to vote or to direct the vote:

     

    15,376,197 (1)

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    15,376,197 (1)

     

     

     

     

      (1) Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of Common Stock is comprised of (a) 8,246,592 shares of Common Stock and (b) 7,129,605 shares of Common Stock issuable upon exercise of the Warrants, which, in each case, are owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC.  The reported securities be deemed beneficially owned by Redmile Group, LLC as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

     

      (2) Percentage based on (i) 296,590,931 shares of Common Stock outstanding as of July 26, 2024, as reported by the Issuer in the Form 10-Q, plus (ii) 7,129,605 shares of Common Stock issuable upon exercise of certain of the Warrants.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A.

     

    Item 9. Notice of Dissolution of Group.

     

    N/A.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024

     

      Redmile Group, LLC
         
      By: /s/ Jeremy C. Green
       

    Name: Jeremy C. Green

    Title: Managing Member

     

        /s/ Jeremy C. Green
        Jeremy C. Green

     

     

     

    Get the next $FOLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FOLD

    DatePrice TargetRatingAnalyst
    12/13/2024$17.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    9/6/2024$18.00Buy
    Jefferies
    5/30/2024$18.00Overweight
    Wells Fargo
    5/14/2024$13.00Neutral → Buy
    Guggenheim
    12/19/2023$15.00 → $20.00Equal-Weight → Overweight
    Morgan Stanley
    9/9/2022$14.00Equal-Weight
    Morgan Stanley
    4/13/2022$11.00Neutral
    Goldman
    2/24/2022$16.00 → $14.00Outperform
    SVB Leerink
    More analyst ratings

    $FOLD
    Leadership Updates

    Live Leadership Updates

    See more
    • Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer

      Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th

      8/21/23 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors

      PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus

      6/14/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amicus Therapeutics Appoints Sébastien Martel as Senior Vice President of Strategy and Business Development

      Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President

      5/6/21 7:00:00 AM ET
      $FOLD
      Biotechnology: Pharmaceutical Preparations
      Health Care